帕金森病伴快速眼动睡眠行为障碍患者的谷氨酸能信号
本研究结合磁共振波谱与[11C]ABP688 PET,在16例伴快速眼动睡眠行为障碍(RBD)的帕金森病患者、17例不伴RBD的帕金森病患者和15名健康对照中同时评估谷氨酸能信号。伴RBD患者[11C]ABP688总分布容积(VT)整体升高,而谷氨酸能代谢物组间无差异。
要点
- 伴RBD的帕金森病患者[11C]ABP688总分布容积整体高于不伴RBD患者和健康对照。
- 谷氨酸、谷氨酰胺和谷胱甘肽水平在组间无差异,且与[11C]ABP688区域总分布容积不相关。
- [11C]ABP688总分布容积与无肌张力REM睡眠量及多巴胺能治疗反应相关。
核心结论
- 结果提示伴RBD的帕金森病患者虽谷氨酸水平未受影响,但[11C]ABP688总分布容积升高,显示谷氨酸能信号改变。
- 谷氨酸受体与磁共振波谱谷氨酸代谢物水平的不平衡提示参与帕金森病异质性的新机制,并需进一步研究靶向mGluR5的药物。
研究设计与样本
- 结合磁共振波谱与[11C]ABP688 PET于PET/MR混合系统,同时研究帕金森病患者的两种谷氨酸信号机制。
- 患者按隔夜视频多导睡眠图所测RBD状态分组,并与年龄和性别匹配的健康对照比较。
- 采用弹丸-输注方案,在扫描45至60分钟的稳态条件下以代谢物校正血浆浓度估算[11C]ABP688总分布容积(VT)。
- 以左侧基底节单体素受激回波采集模式磁共振波谱检测谷氨酸、谷氨酰胺和谷胱甘肽水平。
主要发现
- 16例伴RBD的帕金森病患者[11C]ABP688总分布容积整体升高,与17例不伴RBD患者和15名健康对照比较(F(2,45)=5.579,p=0.007)。
- 谷氨酸能代谢物组间无差异,且与[11C]ABP688区域总分布容积不相关。
- [11C]ABP688总分布容积与无肌张力REM睡眠量相关(F(1,42)=5.600,p=0.023)。
- [11C]ABP688总分布容积与帕金森病患者的多巴胺能治疗反应相关(F(1,30)=5.823,p=0.022)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinical heterogeneity of patients with Parkinson disease (PD) is well recognized. PD with REM sleep behavior disorder (RBD) is a more malignant phenotype with faster motor progression and higher nonmotor symptom burden. However, the neural mechanisms underlying this clinical divergence concerning imbalances in neurotransmitter systems remain elusive. METHODS: Combining magnetic resonance (MR) spectroscopy and [11C]ABP688 PET on a PET/MR hybrid system, we simultaneously investigated two different mechanisms of glutamate signaling in patients with PD. Patients were grouped according to their RBD status in overnight video-polysomnography and compared with age-matched and sex-matched healthy control (HC) participants. Total volumes of distribution (VT) of [11C]ABP688 were estimated with metabolite-corrected plasma concentrations during steady-state conditions between 45 and 60 minutes of the scan following a bolus-infusion protocol. Glutamate, glutamine, and glutathione levels were investigated with single-voxel stimulated echo acquisition mode MR spectroscopy of the left basal ganglia. RESULTS: We measured globally elevated VT of [11C]ABP688 in 16 patients with PD and RBD compared with 17 patients without RBD and 15 HC participants (F(2,45) = 5.579, p = 0.007). Conversely, glutamatergic metabolites did not differ between groups and did not correlate with the regional VT of [11C]ABP688. VT of [11C]ABP688 correlated with the amount of REM sleep without atonia (F(1,42) = 5.600, p = 0.023) and with dopaminergic treatment response in patients with PD (F(1,30) = 5.823, p = 0.022). DISCUSSION: Our results suggest that patients with PD and RBD exhibit altered glutamatergic signaling indicated by higher VT of [11C]ABP688 despite unaffected glutamate levels. The imbalance of glutamate receptors and MR spectroscopy glutamate metabolite levels indicates a novel mechanism contributing to the heterogeneity of PD and warrants further investigation of drugs targeting mGluR5.
引用
- Doppler CEJ, Seger A, Farrher E, et al. Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder. Neurology. 2024. PMID: 38630966. doi:10.1212/WNL.0000000000209271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。